| Literature DB >> 24144185 |
Katharine M Benedict, Sheryl P Gow, Sylvia Checkley, Calvin W Booker, Tim A McAllister, Paul S Morley1.
Abstract
BACKGROUND: The purpose of this study was to objectively compare methodological approaches that might be utilized in designing an antimicrobial resistance (AMR) surveillance program in beef feedlot cattle. Specifically, four separate comparisons were made to investigate their potential impact on estimates for prevalence of AMR. These included investigating potential differences between 2 different susceptibility testing methods (broth microdilution and disc diffusion), between 2 different target bacteria (non-type-specific E. coli [NTSEC] and Mannheimia haemolytica), between 2 strategies for sampling feces (individual samples collected per rectum and pooled samples collected from the pen floor), and between 2 strategies for determining which cattle to sample (cattle that were culture-positive for Mannheimia haemolytica and those that were culture-negative).Entities:
Mesh:
Substances:
Year: 2013 PMID: 24144185 PMCID: PMC3818683 DOI: 10.1186/1746-6148-9-216
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Interpretive criteria for using broth microdilution susceptibility testing reported as minimum inhibitory concentrations (μg/ml)
| Amikacin | ≤16 | 32 | ≥64 | CLSI M100-S22, 2012 |
| Ampicillin | ≤8 | 16 | ≥32 | CLSI M100-S22, 2012 |
| Amoxicillin-Clavulanate | ≤8/4 | 16/8 | ≥32/16 | CLSI M100-S22, 2012 |
| Cefoxitin | ≤8 | 16 | ≥32 | CLSI M100-S22, 2012 |
| Ceftiofur | ≤2 | 4 | ≥8 | CLSI M31-A4, 2013 |
| Ceftriaxone | ≤1 | 2 | ≥4 | CLSI M100-S22, 2012 |
| Chloramphenicol | ≤8 | 16 | ≥32 | CLSI M100-S22, 2012 |
| Ciprofloxacin | ≤1 | 2 | ≥4 | CLSI M100-S21, 2011 |
| Gentamicin | ≤4 | 8 | ≥16 | CLSI M100-S22, 2012 |
| Kanamycin | ≤16 | 32 | ≥64 | CLSI M100-S22, 2012 |
| Nalidixic Acid | ≤16 | - | ≥32 | CLSI M100-S22, 2012 |
| Streptomycin | ≤32 | - | ≥64 | NARMS Executive Report 2009 |
| Sulfisoxazole | ≤256 | - | ≥512 | CLSI M100-S22, 2012 |
| Tetracycline | ≤4 | 8 | ≥16 | CLSI M100-S22, 2012 |
| Trimethoprim-Sulfamethoxazole | ≤2/38 | - | ≥4/76 | CLSI M100-S22, 2012 |
CLSI = Clinical and Laboratory Standards Institute.
Interpretive criteria for using broth microdilution susceptibility testing reported as minimum inhibitory concentrations (μg/ml)
| Amikacin | ≤16 | 32 | ≥64 | *CLSI M100-S22, 2012 |
| Ampicillin | ≤0.5 | - | - | CLSI M45-A2, 2010 |
| Amoxicillin-Clavulanate | ≤0.5/0.25 | - | - | CLSI M45-A2, 2010 |
| Cefoxitin | ≤8 | 16 | ≥32 | *CLSI M100-S22, 2012 |
| Ceftiofur | ≤2 | 4 | ≥8 | CSLI M31-A4, 2013 |
| Ceftriaxone | ≤1 | 2 | ≥4 | *CLSI M100-S22, 2012 |
| Chloramphenicol | ≤8 | 16 | ≥32 | *CLSI M100-S22, 2012 |
| Ciprofloxacin | ≤1 | 2 | ≥4 | *CLSI M100-S21, 2011 |
| Gentamicin | ≤4 | 8 | ≥16 | *CLSI M100-S22, 2012 |
| Kanamycin | ≤16 | 32 | ≥64 | *CLSI M100-S22, 2012 |
| Nalidixic Acid | ≤16 | - | ≥32 | *CLSI M100-S22, 2012 |
| Streptomycin | ≤32 | - | ≥64 | NARMS Executive Report 2009 |
| Sulfisoxazole | ≤256 | - | ≥512 | *CLSI M100-S22, 2012 |
| Tetracycline | ≤2 | 4 | ≥8 | CLSI M31-A4, 2013 |
| Trimethoprim-Sulfamethoxazole | ≤0.5/9.5 | - | - | CLSI M45-A2, 2010 |
*Interpretive criteria for E. coli used in lieu of M. haemolytica since CLSI does not define breakpoints for M. haemolytica and these antimicrobial drugs.
CLSI = Clinical and Laboratory Standards Institute.
Interpretive criteria for using disk diffusion susceptibility testing reported as inhibition zone diameters (mm)
| Ampicillin | 10 | ≥17 | 14-16 | ≤13 | CLSI M100-S22, 2012 |
| Amoxicillin- Clavulanate | 20/10 | ≥18 | 14-17 | ≤13 | CLSI M100-S22, 2012 |
| Ceftazidine | 30 | ≥18 | 15-17 | ≤14 | CLSI M100-S18, 2008 |
| Ceftiofur | 30 | ≥21 | 18-20 | ≤17 | CLSI M31-A4, 2013 |
| Enrofloxacin | 5 | ≥21 | 17-20 | ≤16 | *CLSI M31-A4, 2013 |
| Florfenicol | 30 | ≥19 | 15-18 | ≤14 | *CLSI M31- A4, 2013 |
| Neomycin | 30 | ≥17 | - | ≤12 | *CLSI M31-A3, 2008 |
| Streptomycin | 10 | ≥15 | 12-14 | ≤11 | CLSI M100-S18, 2008 |
| Sulfisoxazole | 300 | ≥17 | 13-16 | ≤12 | CLSI M100-S22, 2012 |
| Tetracycline | 30 | ≥15 | 12-14 | ≤11 | CLSI M31-A4, 2013 |
| Trimethoprim-Sulfamethoxazole | 1.25/23.75 | ≥16 | 11-15 | ≤10 | CLSI M100-S22, 2012 |
*Interpretive criteria for M. haemolytica used in lieu of E. coli since CLSI does not define breakpoints for E. coli in cattle for these antimicrobial drugs.
CLSI = Clinical and Laboratory Standards Institute.
Interpretive criteria for using disk diffusion susceptibility testing reported as inhibition zone diameters in (mm)
| Ampicillin | 10 | ≥27 | - | - | CLSI M45-A2, 2010 |
| Amoxicillin- Clavulanate | 20/10 | ≥27 | - | - | CLSI M45-A2, 2010 |
| Ceftiofur | 30 | ≥21 | 18-20 | ≤17 | CLSI M31-A3, 2008 |
| Danofloxacin | 5 | ≥22 | - | - | CLSI M31-A3, 2008 |
| Enrofloxacin | 5 | ≥21 | 17-20 | ≤16 | CLSI M31-A4, 2013 |
| Florfenicol | 30 | ≥19 | 15-18 | ≤14 | CLSI M31-A4, 2013 |
| Gentamicin | 10 | ≥15 | - | ≤12 | Catry et al., 2007 |
| Spectinomycin | 100 | ≥14 | 11-13 | ≤10 | CLSI M31-A3, 2008 |
| Sulfisoxazole | 300 | ≥17 | 13-16 | ≤12 | CLSI M31-A3, 2008 |
| Tetracycline | 30 | ≥23 | - | - | CLSI M45-A2, 2010 |
| Tilmicosin | 15 | ≥14 | 11-13 | ≤10 | CLSI M31-A4, 2013 |
| Trimethoprim-Sulfamethoxazole | 1.25/23.75 | ≥24 | - | - | CLSI M45-A2, 2010 |
| Tulathromycin | 30 | ≥18 | 15-17 | ≤14 | CLSI M31-A4, 2013 |
CLSI = Clinical and Laboratory Standards Institute.
Likelihood of identifying resistance in isolates of NTSEC or when tested using disk diffusion versus broth microdilution
| Ampicillin | DD3 | 6.3 | 2.9 – 14.3 | <0.0001 | 20.0 | 5.0 – 100 | <0.0001 |
| | BM4 | ref | | | ref | | |
| Amoxicillin-Clavulanate | DD | −5 | – | – | 10.0 | 3.0 – 33.3 | 0.0001 |
| | BM | | | | ref | | |
| Ceftiofur | DD | 5.6 | 1.2 – 25.0 | 0.03 | −5 | – | – |
| | BM | ref | | | | | |
| Streptomycin | DD | 2.0 | 1.6 – 2.7 | <0.0001 | −5 | – | – |
| | BM | ref | | | | | |
| Sulfisoxazole | DD | 1.3 | 0.9 – 1.9 | 0.11 | −5 | – | – |
| | BM | ref | | | | | |
| Tetracycline | DD | 0.6 | 0.5 – 0.8 | 0.0003 | 25.0 | 7.7 – 100 | <0.0001 |
| | BM | ref | | | ref | | |
| TMS6 | DD | 4.8 | 2.0 – 11.1 | 0.0004 | −5 | – | – |
| BM | ref | ||||||
1Odds ratio comparing disk diffusion to broth microdilution as the reference category.
295% confidence intervals determined using Wald statistics.
3Disk Diffusion.
4Broth Microdilution.
5Model was not stable because of low resistance prevalence.
6Trimethoprim-Sulfamethoxazole.
Likelihood of identifying resistance among paired isolates of NTSEC and that were recovered from the same individuals on the same day (n=2190)
| Ampicillin | NTSEC | 3.1 | 2.0 - 4.8 | <0.0001 |
| | Reference | | | |
| Kanamycin | NTSEC | 0.2 | 0.1 - 0.3 | <0.0001 |
| | Reference | | | |
| Nalidixic acid | NTSEC | 4.0 | 0.8 - 20.0 | 0.08 |
| | Reference | | | |
| Streptomycin | NTSEC | 3.3 | 3.3 - 10.7 | <0.0001 |
| | Reference | | | |
| Sulfisoxazole | NTSEC | 50.0 | 25.0 - 100.0 | <0.0001 |
| | Reference | | | |
| Tetracycline | NTSEC | 33.3 | 50.0 - 100.0 | <0.0001 |
| | Reference | | | |
| Trimethoprim- Sulfamethoxazole | NTSEC | 11.1 | 2.7 - 50.0 | 0.001 |
| Reference |
1Susceptibility testing was performed using broth microdilution.
2Other drugs could not be analyzed because of low resistance prevalence (amikacin, amoxicillin-clavulanate, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, and nalidixic acid).
3Odds ratio.
495% confidence intervals determined using Wald statistics.
Likelihood of identifying resistance among NTSEC isolates cultured from feces collected as composite pen floor samples or as individual samples collected per rectum on the same sampling days
| Ampicillin | Individual | 0.8 | 0.3 – 1.8 | 0.58 |
| | Composite | Reference | | |
| Chloramphenicol | Individual | 0.9 | 0.4 – 2.5 | 0.94 |
| | Composite | Reference | | |
| Kanamycin | Individual | 0.6 | 0.2 – 2.5 | 0.5 |
| | Composite | Reference | | |
| Nalidixic Acid | Individual | 3.5 | 0.3 – 44.8 | 0.41 |
| | Composite | Reference | | |
| Streptomycin | Individual | 1.3 | 0.8 – 2.2 | 0.31 |
| | Composite | Reference | | |
| Sulfisoxazole | Individual | 1.2 | 0.7 – 2.2 | 0.5 |
| | Composite | Reference | | |
| Tetracycline | Individual | 0.9 | 0.6 – 1.7 | 0.92 |
| | Composite | Reference | | |
| Trimethoprim- Sulfamethoxazole | Individual | 1.7 | 0.4 – 8.5 | 0.5 |
| Composite | Reference |
1n=412 isolates recovered from 137 fecal samples collected from individual cattle, and n=198 isolates recovered from 40 composite pen floor fecal samples.
2Susceptibility testing was performed using broth microdilution.
3Other drugs could not be analyzed because of low resistance prevalence (amikacin, amoxicillin-clavulanate, cefoxitin, ceftiofur, ceftriaxone, ciprofloxacin, gentamicin, and nalidixic acid).
4 Odds Ratio. Analyses controlled for potential lack of independence related to repeated measures and hierarchical data structure using generalized estimating equations.
595% confidence intervals.
Likelihood of identifying resistance among NTSEC isolates recovered from individuals that were culture-positive for to those that were culture-negative, stratified by sample time
| Ampicillin | First | Positive | 1.2 | 0.3 – 4.8 | 0.78 |
| | | Negative | ref | | |
| | Second | Positive | 3.3 | 0.4 – 26.8 | 0.19 |
| | | Negative | ref | | |
| Streptomycin | First | Positive | 0.4 | 0.2 – 0.9 | 0.04 |
| | | Negative | ref | | |
| | Second | Positive | 0.5 | 0.1 – 2.3 | 0.46 |
| | | Negative | ref | | |
| Sulfisoxazole | First | Positive | 0.8 | 0.4 – 1.7 | 0.56 |
| | | Negative | ref | | |
| | Second | Positive | 1.5 | 0.5 – 4.4 | 0.50 |
| | | Negative | ref | | |
| Teteracyline | First | Positive | 1.1 | 0.5 – 2.5 | 0.82 |
| | | Negative | ref | | |
| | Second | Positive | 0.9 | 0.4 – 2.2 | 0.90 |
| Negative | ref |
1n=377 isolates recovered from 186 individuals that were culture-positive for MH, and n=225 isolates recovered from 77 individuals that were culture-negative for MH.
2Susceptibility testing was performed using broth microdilution.
3Other drugs could not be analyzed because of low resistance prevalence (amikacin, amoxicillin-clavulanate, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, trimethoprim-sulfamethoxazole).
4Culture status regarding recovery of M. haemolytica from nasopharyngeal swabs.
5Analyses controlled for repeated measures and hierarchical data structure using generalized estimating equations (GEE), and fixed effects for feedlot, sample time, M. haemolytica culture-status, and a single interaction term for sample time*M. haemolytica culture-status.
695% confidence intervals.